{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:13:51Z","timestamp":1791411231832,"version":"4.3.3"},"reference-count":120,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"5","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2012]]},"DOI":"10.2133\/dmpk.dmpk-12-rv-042","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T23:06:50Z","timestamp":1342652810000},"page":"466-477","source":"Crossref","is-referenced-by-count":226,"title":["The Emerging Role of Human Esterases"],"prefix":"10.2133","volume":"27","author":[{"given":"Tatsuki","family":"Fukami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>: 1201&ndash;1208 (2004).","DOI":"10.1124\/dmd.104.000794"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Watanabe, A., Fukami, T., Nakajima, M., Takamiya, M., Aoki, Y. and Yokoi, T.: Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. <i>Drug Metab. Dispos.<\/i>, <b>37<\/b>: 1513&ndash;1520 (2009).","DOI":"10.1124\/dmd.109.026567"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Watanabe, A., Fukami, T., Takahashi, S., Kobayashi, Y., Nakagawa, N., Nakajima, M. and Yokoi, T.: Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. <i>Drug Metab. Dispos.<\/i>, <b>38<\/b>: 1532&ndash;1537 (2010).","DOI":"10.1124\/dmd.110.033720"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Nakajima, A., Fukami, T., Kobayashi, Y., Watanabe, A., Nakajima, M. and Yokoi, T.: Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. <i>Biochem. Pharmacol.<\/i>, <b>82<\/b>: 1747&ndash;1756 (2011).","DOI":"10.1016\/j.bcp.2011.08.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Iwamura, A., Fukami, T., Higuchi, R., Nakajima, M. and Yokoi, T.: Human &alpha;\/&beta; hydrolase domain containing 10 (ABHD10) is a responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. <i>J. Biol. Chem.<\/i>, <b>287<\/b>: 9240&ndash;9249 (2012).","DOI":"10.1074\/jbc.M111.271288"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Holmes, R. S., Wright, M. W., Laulederkind, S. J., Cox, L. A., Hosokawa, M., Imai, T., Ishibashi, S., Lehner, R., Miyazaki, M., Perkins, E. J., Potter, P. M., Redinbo, M. R., Robert, J., Satoh, T., Yamashita, T., Yan, B., Yokoi, T., Zechner, R. and Maltais, L. J.: Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. <i>Mamm. Genome<\/i>, <b>21<\/b>: 427&ndash;441 (2010).","DOI":"10.1007\/s00335-010-9284-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fukami, T., Nakajima, M., Maruichi, T., Takahashi, S., Takamiya, M., Aoki, Y., McLeod, H. L. and Yokoi, T.: Structure and characterization of human <i>carboxylesterase 1A1, 1A2<\/i>, and <i>1A3<\/i> genes. <i>Pharmacogenet. Genomics<\/i>, <b>18<\/b>: 911&ndash;920 (2008).","DOI":"10.1097\/FPC.0b013e32830b0c5e"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Imai, T.: Human carboxylesterase isozymes: catalytic properties and rational drug design. <i>Drug Metab. Pharmacokinet.<\/i>, <b>21<\/b>: 173&ndash;185 (2006).","DOI":"10.2133\/dmpk.21.173"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Brzezinski, M. R., Abraham, T. L., Stone, C. L., Dean, R. A. and Bosron, W. F.: Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzylecgonine and the formation of cocaethylene from alcohol and cocaine. <i>Biochem. Pharmacol.<\/i>, <b>48<\/b>: 1747&ndash;1755 (1994).","DOI":"10.1016\/0006-2952(94)90461-8"},{"key":"10","unstructured":"10) Xu, G., Zhang, W., Ma, M. K. and McLeod, H. L.: Human carboxylesterase 2 is commonly expressed in tumor tissues and is correlated with activation of irinotecan. <i>Clin. Cancer Res.<\/i>, <b>8<\/b>: 2605&ndash;2611 (2002)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Pindel, E. V., Kedishvili, N. Y., Abraham, T. L., Brzezinski, M. R., Zhang, J., Dean, R. A. and Bosron, W. F.: Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. <i>J. Biol. Chem.<\/i>, <b>272<\/b>: 14769&ndash;14775 (1997).","DOI":"10.1074\/jbc.272.23.14769"},{"key":"12","unstructured":"12) Potter, P. M., Wolverton, J. S., Morton, C. L., Wierdl, M. and Danks, M. K.: Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. <i>Cancer Res.<\/i>, <b>58<\/b>: 3627&ndash;3632 (1998)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tabata, T., Katoh, M., Tokudome, S., Nakajima, M. and Yokoi, T.: Identification of the cytosolic carboxylesterase catalyzing the 5&prime;-deoxy-5-fluorocytidine formation from capecitabine in human liver. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>: 1103&ndash;1110 (2004).","DOI":"10.1124\/dmd.104.000554"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Takai, S., Matsuda, A., Usami, Y., Adachi, T., Sugiyama, T., Katagiri, Y., Tatematsu, M. and Hirano, K.: Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and pI 4.5 from human liver. <i>Biol. Pharm. Bull.<\/i>, <b>20<\/b>: 869&ndash;873 (1997).","DOI":"10.1248\/bpb.20.869"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sun, Z., Murry, D. J., Sanghani, S. P., Davis, W. I., Kedishvili, N. Y., Zou, Q., Hurley, T. D. and Bosron, W. F.: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>310<\/b>: 469&ndash;476 (2004).","DOI":"10.1124\/jpet.104.067116"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Shi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., You, L., Akhlaghi, F. and Yan, B.: Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by anitplatelet agent clopidogrel. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>319<\/b>: 1477&ndash;1484 (2006).","DOI":"10.1124\/jpet.106.111807"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tang, M., Mukundan, M., Yang, J., Charpentier, N., LeCluyse, E. L., Black, C., Yang, D., Shi, D. and Yan, B.: Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>319<\/b>: 1467&ndash;1476 (2006).","DOI":"10.1124\/jpet.106.110577"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tabata, T., Katoh, M., Tokudome, S., Hosokawa, M., Chiba, K., Nakajima, M. and Yokoi, T.: Bioactivation of capecitabine in human liver: Involvement of the cytosolic enzyme on 5&prime;-deoxy-5-fluorocytidine formation. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>: 762&ndash;767 (2004).","DOI":"10.1124\/dmd.32.7.762"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sato, Y., Miyashita, A., Iwatsubo, T. and Usui, T.: Conclusive identification of the oxybutinin-hydrolyzing enzyme in human liver. <i>Drug Metab. Dispos.<\/i>, <b>40<\/b>: 902&ndash;906 (2012).","DOI":"10.1124\/dmd.111.043208"},{"key":"20","unstructured":"20) Humerickhouse, R., Lohrbach, L., Li, L., Borson, W. F. and Dolan, M. E.: Characterization of irinotecan hydrolysis by human liver carboxyelsterase isoforms hCE-1 and hCE-2. <i>Cancer Res.<\/i>, <b>60<\/b>: 1189&ndash;1192 (2000)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Williams, E. T., Jones, K. O., Ponsler, G. D., Lowery, S. M., Perkins, E. J., Wrighton, S. A., Ruterbories, K. J., Kazui, M. and Farid, N. A.: The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. <i>Drug Metab. Dispos.<\/i>, <b>36<\/b>: 1227&ndash;1232 (2008).","DOI":"10.1124\/dmd.107.020248"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Zhu, H. J., Patrick, K. S., Yuan, H. J., Wang, J. S., Donovan, J. L., DeVane, C. L., Malcolm, R., Johnson, J. A., Youngblood, G. L., Sweet, D. H., Langaee, T. Y. and Markowitz, J. S.: Two CES1 gene mutations lead to dysfunctional carboxylesterase1 activity in man: clinical significance and molecular basis. <i>Am. J. Hum. Genet.<\/i>, <b>82<\/b>: 1241&ndash;1248 (2008).","DOI":"10.1016\/j.ajhg.2008.04.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Zhu, H. J., Appel, D. I., Johnson, J. A., Chavin, K. D. and Markowitz, J. S.: Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. <i>Biochem. Pharmacol.<\/i>, <b>77<\/b>: 1266&ndash;1272 (2009).","DOI":"10.1016\/j.bcp.2008.12.017"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kubo, T., Kim, S.-R., Sai, K., Saito, Y., Nakajima, T., Matsumoto, K., Saito, H., Shirao, K., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Ohno, Y., Ozawa, S. and Sawada, J.-I.: Functional characterization of three naturally occurring single nucleotide polymorphisms in the <i>CES2<\/i> gene encoding carboxylesterase 2 (HCE-2). <i>Drug Metab. Dispos.<\/i>, <b>33<\/b>: 1482&ndash;1487 (2005).","DOI":"10.1124\/dmd.105.005587"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. and Yokoi, T.: In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. <i>Drug Metab. Dispos.<\/i>, <b>38<\/b>: 2173&ndash;2178 (2010).","DOI":"10.1124\/dmd.110.034454"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Ovnic, M., Swank, R. T., Fletcher, C., Zhen, L., Novak, E. K., Baumann, H., Heintz, N. and Ganschow, R. E.: Characterization and functional expression of a cDNA enzoding egasyn (esterase-22): the endoplasmic reticulum-targeting protein of &beta;-glucuronidase. <i>Genomics<\/i>, <b>11<\/b>: 956&ndash;967 (1991).","DOI":"10.1016\/0888-7543(91)90020-F"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Li, B., Sediacek, M., Manoharan, I., Boopathy, R., Duysen, E. G., Masson, P. and Lockridge, O.: Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. <i>Biochem. Pharmacol.<\/i>, <b>70<\/b>: 1673&ndash;1684 (2005).","DOI":"10.1016\/j.bcp.2005.09.002"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Morton, C. L., Iacono, L., Hyatt, J. L., Taylor, K. R., Cheshire, P. J., Houghton, P. J., Danks, M. K., Stewart, C. F. and Potter, P. M.: Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. <i>Cancer Chemother. Pharmacol.<\/i>, <b>56<\/b>: 629&ndash;636 (2005).","DOI":"10.1007\/s00280-005-1027-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Luan, L., Sugiyama, T., Takai, S., Usami, Y., Adachi, T., Katagiri, Y. and Hirano, K.: Purification and characterization of pranlukast hydrolase from rat liver microsomes: the hydrolase is identical to carboxylesterase pI 6.2. <i>Biol. Pharm. Bull.<\/i>, <b>20<\/b>: 71&ndash;75 (1997).","DOI":"10.1248\/bpb.20.71"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Frick, C., Atanasov, A. G., Arnold, P., Ozols, J. and Odermatt, A.: Appropriate function of 11&beta;-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase. <i>J. Biol. Chem.<\/i>, <b>279<\/b>: 31131&ndash;31138 (2004).","DOI":"10.1074\/jbc.M313666200"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Probst, M. R., Jen&ouml;, P. and Meyer, U. A.: Purification and characterization of a human liver arylacetamide deacetylase. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>177<\/b>: 453&ndash;459 (1991).","DOI":"10.1016\/0006-291X(91)92005-5"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Probst, M. R., Beer, M., Beer, D., Jeno, P., Meyer, U. A. and Gasser, R.: Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylacetamide carcinogens with high sequence similarity to hormone-sensitive lipase. <i>J. Biol. Chem.<\/i>, <b>269<\/b>: 21650&ndash;21656 (1994).","DOI":"10.1016\/S0021-9258(17)31855-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Tiwari, R., Koffel, R. and Schneiter, R.: An acetylation\/deacetylation cycle controls the export of sterols and steroid from <i>S. cerevisiae<\/i>. <i>EMBO J.<\/i>, <b>26<\/b>: 5109&ndash;5119 (2007).","DOI":"10.1038\/sj.emboj.7601924"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Thole, Z., Manso, G., Salgueiro, E., Revuelta, P. and Hidalgo, A.: Hepatotoxicity induced by antiandrogens: a review of the literature. <i>Urol. Int.<\/i>, <b>73<\/b>: 289&ndash;295 (2004).","DOI":"10.1159\/000081585"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Fau, D., Eugene, D., Berson, A., Letteron, P., Fromenty, B., Fisch, C. and Pessayre, D.: Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>269<\/b>: 954&ndash;962 (1994).","DOI":"10.1016\/S0022-3565(25)38899-3"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Katchen, B. and Buxbaum, S.: Disposition of a new, nonsteroid, antiandrogen, &alpha;,&alpha;,&alpha;-trifluoro-2-methyl-4&prime;-nitro-<i>m<\/i>-propionotoluidine (Flutamide), in men following a single oral 200 mg dose. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>41<\/b>: 373&ndash;379 (1975).","DOI":"10.1210\/jcem-41-2-373"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Schulz, M., Scmoldt, A., Donn, F. and Becker, H.: The pharmacokinetics of flutamide and its metabolites after a single oral dose and during chronic treatment. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>34<\/b>: 633&ndash;636 (1988).","DOI":"10.1007\/BF00615229"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kobayashi, Y., Fukami, T., Shimizu, M., Nakajima, M. and Yokoi, T.: Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. <i>Drug Metab. Dispos.<\/i>, <b>40<\/b>: 1080&ndash;1084 (2012).","DOI":"10.1124\/dmd.112.044537"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Uetrecht, J.: <i>N<\/i>-oxydation of drugs associated with idiosyncratic drug reactions. <i>Drug Metab. Rev.<\/i>, <b>34<\/b>: 651&ndash;665 (2002).","DOI":"10.1081\/DMR-120005667"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Aizawa, Y., Ikemoto, I., Kishimoto, K., Wada, T., Yamazaki, H., Ohishi, Y., Kiyota, H., Furuta, N., Sunuki, H. and Ueda, M.: Flutamide-induced heoatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. <i>Mol. Cell. Biochem.<\/i>, <b>252<\/b>: 149&ndash;156 (2003).","DOI":"10.1023\/A:1025560513308"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Matsuzaki, Y., Nagai, D., Ichimura, E., Goda, R., Tomura, A., Doi, M. and Nishikawa, K.: Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. <i>J. Gastroenterol.<\/i>, <b>41<\/b>: 231&ndash;239 (2006).","DOI":"10.1007\/s00535-005-1749-y"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Ohbuchi, M., Miyata, M., Nagai, D., Shimada, M., Yoshinari, K. and Yamazoe, Y.: Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. <i>Drug Metab. Dispos.<\/i>, <b>37<\/b>: 97&ndash;105 (2009).","DOI":"10.1124\/dmd.108.021964"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Sicardi, S. M., Martiarena, J. L. and Iglesias, M. T.: Mutagenic and analgesic activities of aniline derivatives. <i>J. Pharm. Sci.<\/i>, <b>80<\/b>: 761&ndash;764 (1991).","DOI":"10.1002\/jps.2600800811"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. and Yu, M. C.: Regular use of analgesics is a risk factor for renal cell carcinoma. <i>Br. J. Cancer<\/i>, <b>81<\/b>: 542&ndash;548 (1999).","DOI":"10.1038\/sj.bjc.6690728"},{"key":"45","unstructured":"45) Vaught, J. B., McGarney, P. B., Lee, M. S., Garner, C. D., Wang, C. Y., Linsmainer-Bednar, E. M. and King, C. M.: Activation of N-hydroxyphenacetin to mutagenic and nucleic acid-binding metabolites by acyltransfer, deacylation, and sulfate conjugation. <i>Cancer Res.<\/i>, <b>41<\/b>: 3424&ndash;3429 (1981)."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Wirth, P. J., Alewood, P., Calder, I. and Thorgeirsson, S. S.: Mutagenecity of N-hydroxy-2-acetylaminofluorene and N-hydroxy-phenacetin and their respective deacetylated metabolites in nitroreductase deficient <i>Salmonella<\/i> TA98FR and TA100FR. <i>Carcinogenesis<\/i>, <b>3<\/b>: 167&ndash;170 (1982).","DOI":"10.1093\/carcin\/3.2.167"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Jensen, C. B. and Jollow, D. J.: The role of <i>N<\/i>-hydroxyphenetidine in phenacetin-induced hemolytic anemia. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>111<\/b>: 1&ndash;12 (1991).","DOI":"10.1016\/0041-008X(91)90128-2"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Kobayashi, Y., Fukami, T., Higuchi, R., Nakajima, M. and Yokoi, T.: Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. <i>Biochem. Pharmacol.<\/i>, in press.","DOI":"10.1016\/j.bcp.2012.08.015"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Yew, W. W. and Leung, C. C.: Antituberculosis drugs and hepatotoxicity. <i>Respirology<\/i>, <b>11<\/b>: 699&ndash;707 (2006).","DOI":"10.1111\/j.1440-1843.2006.00941.x"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Shimizu, M., Fukami, T., Kobayashi, Y., Takamiya, M., Aoki, Y., Nakajima, M. and Yokoi, T.: A novel polymorphic allele of human arylacetamide deacetylase leads to diminished enzyme activity. <i>Drug Metab. Dispos.<\/i>, <b>40<\/b>: 1183&ndash;1190 (2012).","DOI":"10.1124\/dmd.112.044883"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Kobayashi, Y., Fukami, T., Nakajima, A., Watanabe, A., Nakajima, M. and Yokoi, T.: Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. <i>Drug Metab. Dispos.<\/i>, <b>40<\/b>: 671&ndash;679 (2012).","DOI":"10.1124\/dmd.111.043067"},{"key":"52","unstructured":"52) Tenconi, L. T. and Beretta, E.: Urinary and biliary metabolites of rifampicin in different animal species. In: The Problems of Species Differences and Statistics in Toxicology, Proc. Europ. Soc. For study of drug Toxicity, Vol. II; Excerpta Med. Int. Congr. Ser. No. 198, Excerpta Medica, Amsterdam, pp. 80&ndash;85 (1970)."},{"key":"53","unstructured":"53) Chan, K.: A simultaneous determination of rifampin and 25-deacetylrifampicin in cerebrospinal fluid and plasma of rabbit by liquid chromatography. <i>Zhongguo. Yao. Li. Xue. Bao.<\/i>, <b>8<\/b>: 555&ndash;559 (1987)."},{"key":"54","unstructured":"54) Binda, G., Domenichini, E., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B. and Fowst, G.: Rifampicin, a general review. <i>Arzneimittelforschung<\/i>, <b>21<\/b>: 1907&ndash;1977 (1971)."},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Gnatt, A., Ginzberg, D., Lieman-Hurwitz, J., Zamir, R., Zakut, H. and Soreq, H.: Human acetylcholinesterase and butyrylcholinesterase are encoded by two distinct genes. <i>Cell. Mol. Neurobiol.<\/i>, <b>11<\/b>: 91&ndash;104 (1991).","DOI":"10.1007\/BF00712802"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Karpel, R., Ben Aziz-Aloya, R., Sternfeld, M., Ehrlich, G., Ginzberg, D., Tarroni, P., Clementi, F., Zakut, H. and Soreq, H.: Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. <i>Exp. Cell Res.<\/i>, <b>210<\/b>: 268&ndash;277 (1994).","DOI":"10.1006\/excr.1994.1039"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Chatonnet, A. and Lockridge, O.: Comparison of butyrylcholinesterase and acetylcholinesterase. <i>Biochem. J.<\/i>, <b>260<\/b>: 625&ndash;634 (1989).","DOI":"10.1042\/bj2600625"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Takeda, M., Tanaka, T. and Okochi, M.: New drugs for Alzheimer's disease in Japan. <i>Psychiatry Clin. Neurosci.<\/i>, <b>65<\/b>: 399&ndash;404 (2011).","DOI":"10.1111\/j.1440-1819.2011.02253.x"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Jbilo, O., Bartels, C. F., Chatonnet, A., Toutant, J. P. and Lockridge, O.: Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. <i>Toxicon<\/i>, <b>32<\/b>: 1445&ndash;1457 (1994).","DOI":"10.1016\/0041-0101(94)90416-2"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Lockridge, O., Bartels, C. F., Vaughan, T. A., Wong, C. K., Norton, S. E. and Johnson, L. L.: Complete amino acid sequence of human serum cholinesterase. <i>J. Biol. Chem.<\/i>, <b>262<\/b>: 549&ndash;557 (1987).","DOI":"10.1016\/S0021-9258(19)75818-9"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) P&eacute;rez Guillermo, F., Martinez Pretel, C. M., Tar&iacute;n Royo, F., Pe&ntilde;a Macias, M. J., Alvarez Ossorio, J. A. and Vidal, C. J.: Prolonged suxamethonium-induced neuromuscular blockade associated with organophosphate poisoning. <i>Br. J. Anaesth.<\/i>, <b>61<\/b>: 233&ndash;236 (1988).","DOI":"10.1093\/bja\/61.2.233"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) &Oslash;stergaard, D., Jensen, F. S., Jensen, E., Skovgaard, L. T. and Viby-Mogensen, J.: Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase. <i>Acta Anaesthesiol. Scand.<\/i>, <b>37<\/b>: 314&ndash;318 (1993).","DOI":"10.1111\/j.1399-6576.1993.tb03721.x"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Vaisi-Raygani, A., Rahimi, Z., Kharazi, H., Tavilani, H., Aminiani, M., Kiani, A., Vaisi-Raygani, A. and Pourmotabbed, T.: Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran. <i>Clin. Biochem.<\/i>, <b>40<\/b>: 629&ndash;633 (2007).","DOI":"10.1016\/j.clinbiochem.2007.01.018"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Stewart, D. J., Inaba, T., Lucassen, M. and Kalow, W.: Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases. <i>Clin. Pharmacol. Ther.<\/i>, <b>25<\/b>: 464&ndash;468 (1979).","DOI":"10.1002\/cpt1979254464"},{"key":"65","unstructured":"65) Morton, C. L., Wadkins, M., Danks, M. K. and Potter, P. M.: The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. <i>Cancer Res.<\/i>, <b>59<\/b>: 1458&ndash;1463 (1999)."},{"key":"66","unstructured":"66) Kuo, C. L. and La Du, B. N.: Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. <i>Drug Metab. Dispos.<\/i>, <b>26<\/b>: 653&ndash;660 (1998)."},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Primo-Parmo, S. L., Sorenson, R. C., Teiber, J. and La Du, B. N.: The human serum paraoxonase\/arylesterase gene (<i>PON1<\/i>) is one member of a multiple family. <i>Genomics<\/i>, <b>33<\/b>: 498&ndash;507 (1996).","DOI":"10.1006\/geno.1996.0225"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Draganov, D. I. and La Du, B. N.: Pharmacogenetics of paraoxonases: a brief review. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>369<\/b>: 78&ndash;88 (2004).","DOI":"10.1007\/s00210-003-0833-1"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Ng, C. J., Wadleigh, D. J., Gangopadhyay, A., Hama, S., Grijalva, V. R., Navab, M., Fogelman, A. M. and Reddy, S. T.: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. <i>J. Biol. Chem.<\/i>, <b>276<\/b>: 44444&ndash;44449 (2001).","DOI":"10.1074\/jbc.M105660200"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Gonzalvo, M. C., Gil, F., Hernandez, A. F., Rodrigo, L., Villanueva, E. and Pla, A.: Human liver paraoxonase (PON1): subcellular distribution and characterization. <i>J. Biochem. Mol. Toxicol.<\/i>, <b>12<\/b>: 61&ndash;69 (1998).","DOI":"10.1002\/(SICI)1099-0461(1998)12:1<61::AID-JBT8>3.0.CO;2-N"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Gaidukov, L. and Tawfik, D. S.: High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. <i>Biochemistry<\/i>, <b>44<\/b>: 11843&ndash;11854 (2005).","DOI":"10.1021\/bi050862i"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Aldridge, W. N.: Serum esterase I. Two types of esterase (A and B) hydrolyzing <i>p<\/i>-nitrophenyl acetate, propionate and butyrate and a method for their determination. <i>Biochem. J.<\/i>, <b>53<\/b>: 110&ndash;117 (1953).","DOI":"10.1042\/bj0530110"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J. and Furlong, C. E.: The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. <i>Nat. Genet.<\/i>, <b>14<\/b>: 334&ndash;336 (1996).","DOI":"10.1038\/ng1196-334"},{"key":"74","unstructured":"74) Tougou, K., Nakamura, A., Watanabe, S., Okuyama, Y. and Morino, A.: Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antifloxacin agent. <i>Drug Metab. Dispos.<\/i>, <b>26<\/b>: 355&ndash;359 (1998)."},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Hioki, T., Fukami, T., Nakajima, M. and Yokoi, T.: Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. <i>Drug Metab. Dispos.<\/i>, <b>39<\/b>: 1345&ndash;1352 (2011).","DOI":"10.1124\/dmd.111.038141"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Ishizuka, T., Fujimori, I., Nishida, A., Sakurai, H., Yoshigae, Y., Nakahara, K., Kurihara, A., Ikeda, T. and Izumi, T.: Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. <i>Drug Metab. Dispos.<\/i>, <b>40<\/b>: 374&ndash;380 (2012).","DOI":"10.1124\/dmd.111.041475"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C. and La Du, B. N.: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. <i>Drug Metab. Dispos.<\/i>, <b>28<\/b>: 1335&ndash;1342 (2000).","DOI":"10.1016\/S0090-9556(24)15082-9"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Scacchi, R., Corbo, R. M., Rickards, O. and De Stefano, G. F.: New data on the world distribution of paraoxonase (PON1 Gln 192 &rarr; Arg) gene frequencies. <i>Hum. Biol.<\/i>, <b>75<\/b>: 365&ndash;373 (2003).","DOI":"10.1353\/hub.2003.0049"},{"key":"79","unstructured":"79) Ueno, T., Shimazaki, E., Matsumoto, T., Watanabe, H., Tsunemi, A., Takahashi, Y., Mori, M., Hamano, R., Fujioka, T., Soma, M., Matsumoto, K. and Kanmatsuse, K.: Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. <i>Med. Sci. Monit.<\/i>, <b>9<\/b>: CR208&ndash;CR212 (2003)."},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Chen, J., Kumar, M., Chan, W., Berkowitz, G. and Wetmur, J. G.: Increased influence of genetic variation on PON1 activity in neonates. <i>Environ. Health Perspect.<\/i>, <b>111<\/b>: 1403&ndash;1409 (2003).","DOI":"10.1289\/ehp.6105"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Garin, M. C., James, R. W., Dussoix, P., Blanch&eacute;, H., Passa, P., Froguel, P. and Ruiz, J.: Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and icreased risk of cardiovascular disease in diabetes. <i>J. Clin. Invest.<\/i>, <b>99<\/b>: 62&ndash;66 (1997).","DOI":"10.1172\/JCI119134"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Mackness, B., Mackness, M. I., Arrol, T., Turkie, W. and Durrington, P. N.: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modifications. <i>FEBS Lett.<\/i>, <b>423<\/b>: 57&ndash;60 (1998).","DOI":"10.1016\/S0014-5793(98)00064-7"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Brophy, V. H., Hastings, M. D., Clendenning, J. B., Richter, R. J., Jarvik, G. P. and Furlong, C. E.: Polymorphisms in the human paraoxonase (PON1) promoter. <i>Pharmacogenetics<\/i>, <b>11<\/b>: 77&ndash;84 (2001).","DOI":"10.1097\/00008571-200102000-00009"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Teiber, J. F., Horke, S., Haines, D. C., Chowdhary, P. K., Xiao, J., Kramer, G. L., Haley, R. W. and Draganov, D. I.: Dominant role of paraoxonases in inactivation of the <i>Pseudomonas aeruginosa<\/i> quorum-sensing signal <i>N<\/i>-(3-oxododecanoyl)-<small>L<\/small>-homoserine lactone. <i>Infect. Immun.<\/i>, <b>76<\/b>: 2512&ndash;2519 (2008).","DOI":"10.1128\/IAI.01606-07"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Draganov, D. I., Teiber, J. F., Speelman, A., Osawa, Y., Sunahara, R. and La Du, B. N.: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. <i>J. Lipid Res.<\/i>, <b>46<\/b>: 1239&ndash;1247 (2005).","DOI":"10.1194\/jlr.M400511-JLR200"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Campo, S., Sardo, A. M., Campo, G. M., Avenoso, A., Castalbo, M., D&rsquo;Ascola, A., Giunta, E., Calatroni, A. and Saitta, A.: Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. <i>Mutat. Res.<\/i>, <b>546<\/b>: 75&ndash;80 (2004).","DOI":"10.1016\/j.mrfmmm.2003.11.007"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Sanghera, D. K., Manzi, S., Minster, R. L., Shaw, P., Kao, A., Bontempo, F. and Kamboh, M. I.: Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. <i>Ann. Hum. Genet.<\/i>, <b>72<\/b>: 72&ndash;81 (2008).","DOI":"10.1111\/j.1469-1809.2007.00400.x"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Evans, W. E. and Relling, M. V.: Pharmacogenomics: translating functional genomics into rational therapeutics. <i>Science<\/i>, <b>286<\/b>: 487&ndash;491 (1999).","DOI":"10.1126\/science.286.5439.487"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Spahn-Langguth, H. and Benet, L. Z.: Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? <i>Drug Metab. Rev.<\/i>, <b>24<\/b>: 5&ndash;47 (1992).","DOI":"10.3109\/03602539208996289"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Bullingham, R. E., Nicholls, A. J. and Kamm, B. R.: Clinical pharmacokinetics of mycophenolate mofetil. <i>Clin. Pharmacokinet.<\/i>, <b>34<\/b>: 429&ndash;455 (1998).","DOI":"10.2165\/00003088-199834060-00002"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Shipkova, M., Armstrong, V. W., Wieland, E., Niedmann, P. D., Sch&uuml;tz, E., Brennerr-Weiss, G., Voihsel, M., Braun, F. and Oellerich, M.: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. <i>Br. J. Pharmacol.<\/i>, <b>126<\/b>: 1075&ndash;1082 (1999).","DOI":"10.1038\/sj.bjp.0702399"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Wieland, E., Shipkova, M., Schellhaas, U., Sch&uuml;tz, E., Niedmann, P. D., Armstrong, V. W. and Oellerich, M.: Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? <i>Clin. Biochem.<\/i>, <b>33<\/b>: 107&ndash;113 (2000).","DOI":"10.1016\/S0009-9120(99)00101-0"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Shipkova, M., Beck, H., Voland, A., Armstrong, V. W., Gr&ouml;ne, H. J., Oellerich, M. and Wieland, E.: Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. <i>Proteomics<\/i>, <b>4<\/b>: 2728&ndash;2738 (2004).","DOI":"10.1002\/pmic.200300836"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Suzuki, E., Yamamura, N., Ogura, Y., Nakai, D., Kubota, K., Kobayashi, N., Miura, S. and Okazaki, O.: Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. <i>Drug Metab. Dispos.<\/i>, <b>38<\/b>: 1538&ndash;1544 (2010).","DOI":"10.1124\/dmd.110.032938"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Perrier, J., Durand, A., Giardina, T. and Puigserver, A.: Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. <i>Biochimie<\/i>, <b>87<\/b>: 673&ndash;685 (2005).","DOI":"10.1016\/j.biochi.2005.04.002"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Nagai, K., Shimizu, T., Toga, A., Takeya, M., Yokomizo, Y., Sakata, Y., Matsuishi, T. and Kato, H.: Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem\/betamipron. <i>J. Antimicrob. Chemother.<\/i>, <b>39<\/b>: 295&ndash;296 (1997).","DOI":"10.1093\/jac\/39.2.295"},{"key":"97","unstructured":"97) Volland, C., Sun, H., Dammeyer, J. and Benet, L. Z.: Stereoselective degradation of the fenoprofen acyl glucuronide enatiomers and irreversible binding to plasma protein. <i>Drug Metab. Dispos.<\/i>, <b>19<\/b>: 1080&ndash;1086 (1991)."},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Smith, P. C., Song, W. Q. and Rodriguez, R. J.: Covalent binding of etodolac acyl glucuronide to albumin <i>in vitro<\/i>. <i>Drug Metab. Dispos.<\/i>, <b>20<\/b>: 962&ndash;965 (1992).","DOI":"10.1016\/S0090-9556(25)08822-1"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Dubois-Presle, N., Lapicque, F., Maurice, M., Fournel-Gigleux, S., Magdalou, J., Abiteboul, M., Siest, G. and Netter, P.: Stereoselective esterase activity of human serum albumin toward ketoprofen glucuronide. <i>Mol. Pharmacol.<\/i>, <b>47<\/b>: 647&ndash;653 (1995).","DOI":"10.1016\/S0026-895X(25)08584-0"},{"key":"100","unstructured":"100) Sallustio, B. C., Fairchild, B. A. and Pannall, P. R.: Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-&beta;-<small>D<\/small>-glucuronide. <i>Drug Metab. Dispos.<\/i>, <b>25<\/b>: 55&ndash;60 (1997)."},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Herv&eacute;, F., Urien, S., Albengres, S., Duche, J. C. and Tillement, J. P.: Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. <i>Clin. Pharmacokinet.<\/i>, <b>26<\/b>: 44&ndash;58 (1994).","DOI":"10.2165\/00003088-199426010-00004"},{"key":"102","unstructured":"102) Qiu, Y., Burlingame, A. L. and Benet, L. Z.: Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. <i>Drug Metab. Dispos.<\/i>, <b>26<\/b>: 246&ndash;256 (1998)."},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Rowe, B. J. and Meffin, P. J.: Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>230<\/b>: 237&ndash;241 (1984).","DOI":"10.1016\/S0022-3565(25)21410-0"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Smith, P. C., McDonagh, A. F. and Benet, L. Z.: Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>252<\/b>: 218&ndash;224 (1990).","DOI":"10.1016\/S0022-3565(25)13333-8"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Whiting, J. F., Narciso, J. P., Chapman, V., Ransil, B. J., Swank, R. T. and Gollan, J. L.: Deconjugation of bilirubin-IX&alpha; glucuronides: a physiolosic role of hepatic microsomal &beta;-glucuronidase. <i>J. Biol. Chem.<\/i>, <b>268<\/b>: 23197&ndash;23201 (1993).","DOI":"10.1016\/S0021-9258(19)49447-7"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Takematsu, H., Diaz, S., Stoddart, A., Zhang, Y. and Varki, A.: Lysosomal and cytosolic sialic acid 9-<i>O<\/i>-acetylesterase activities can be encoded by one gene via differential usage of a single peptide-encoding exon at the N terminus. <i>J. Biol. Chem.<\/i>, <b>274<\/b>: 25623&ndash;25631 (1999).","DOI":"10.1074\/jbc.274.36.25623"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Usui, S., Kubota, M., Iguchi, K., Kiho, T., Sugiyama, T., Katagiri, Y. and Hirano, K.: Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril. <i>Pharm. Res.<\/i>, <b>20<\/b>: 1309&ndash;1316 (2003).","DOI":"10.1023\/A:1025073720126"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Ishizuka, T., Fujimori, I., Kato, M., Noji-Sakikawa, C., Saito, M., Yoshigae, Y., Kubota, K., Kurihara, A., Izumi, T., Ikeda, T. and Okazaki, O.: Human carboxymethylenebutenolidase as a bioactivation hydrolase of olmesartan medoxomil in liver and intestine. <i>J. Biol. Chem.<\/i>, <b>285<\/b>: 11892&ndash;11902 (2010).","DOI":"10.1074\/jbc.M109.072629"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Laeis, P., P&uuml;chler, K. and Kirch, W.: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. <i>J. Hypertens. Suppl.<\/i>, <b>19<\/b>: S21&ndash;S32 (2001).","DOI":"10.1097\/00004872-200106001-00004"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P. and Smiley, M. L.: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. <i>Clin. Pharmacol. Ther.<\/i>, <b>54<\/b>: 595&ndash;605 (1993).","DOI":"10.1038\/clpt.1993.196"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Kim, I., Chu, X. Y., Kim, S., Provoda, C. J., Lee, K. D. and Amidon, G. L.: Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. <i>J. Biol. Chem.<\/i>, <b>278<\/b>: 25348&ndash;25356 (2003).","DOI":"10.1074\/jbc.M302055200"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Puente, X. S. and L&oacute;pez-Ot&iacute;n, C.: Cloning and expression analysis of a novel human serine hydrolase with sequence similarity to prokaryotic enzymes involved in the degradation of aromatic compounds. <i>J. Biol. Chem.<\/i>, <b>270<\/b>: 12926&ndash;12932 (1995).","DOI":"10.1074\/jbc.270.21.12926"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Lai, L., Xu, Z., Zhou, J., Lee, K. D. and Amidon, G. L.: Molecular basis of prodrug activation by human valacyclovirase, an &alpha;-amino acid ester hydrolase. <i>J. Biol. Chem.<\/i>, <b>283<\/b>: 9318&ndash;9327 (2008).","DOI":"10.1074\/jbc.M709530200"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Kim, I., Song, X., Vig, B. S., Mittal, S., Shin, H. C., Lorenzi, P. J. and Amidon, G. L.: A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. <i>Mol. Pharm.<\/i>, <b>1<\/b>: 117&ndash;127 (2004).","DOI":"10.1021\/mp0499757"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Zhou, G., Marathe, G. K., Willard, B. and McIntyre, T. M.: Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. <i>J. Biol. Chem.<\/i>, <b>286<\/b>: 34820&ndash;34829 (2011).","DOI":"10.1074\/jbc.M111.267161"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Sidhu, R. S. and Blair, A. H.: Human liver aldehyde dehydrogenase. Esterase activity. <i>J. Biol. Chem.<\/i>, <b>250<\/b>: 7894&ndash;7898 (1975).","DOI":"10.1016\/S0021-9258(19)40899-5"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Wei, B., Ni, L., Hurley, T. D. and Weiner, H.: Cooperativity in nicotinamide adenine dinucleotide binding induced by mutations of arginine 475 located at the subunit interface in the human liver mitochondrial class 2 aldehyde dehydrogenase. <i>Biochemistry<\/i>, <b>39<\/b>: 5295&ndash;5302 (2000).","DOI":"10.1021\/bi000028n"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Parajuli, B., Kimble-Hill, A. C., Khanna, M., Ivanova, Y., Meroueh, S. and Hurley, T. D.: Discovery of novel regulators of aldehyde dehydrogenase isoenzymes. <i>Chem. Biol. Interact.<\/i>, <b>191<\/b>: 153&ndash;158 (2011).","DOI":"10.1016\/j.cbi.2011.02.018"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Mackenzie, I. S., Maki-Petaja, K. M., McEniery, C. M., Bao, Y. P., Wallace, S. M., Cheriyan, J., Monteith, S., Brown, M. J. and Wilkinson, I. B.: Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. <i>Arterioscler. Thromb. Vasc. Biol.<\/i>, <b>25<\/b>: 1891&ndash;1895 (2005).","DOI":"10.1161\/01.ATV.0000179599.71086.89"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Li, Y., Zhang, D., Jin, W., Shao, C., Yan, P., Xu, C., Sheng, H., Liu, Y., Yu, J., Xie, Y., Zhao, Y., Lu, D., Nebert, D. W., Harrison, D. C., Huang, W. and Jin, L.: Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. <i>J. Clin. Invest.<\/i>, <b>116<\/b>: 506&ndash;511 (2006).","DOI":"10.1172\/JCI26564"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:23:47Z","timestamp":1743787427000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715305152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"alternative-id":["S1347436715305152"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-12-rv-042","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}